| Literature DB >> 30210683 |
Hong-Wei Wang1, Yi-He Chen2, Yan-Yan Chen3, Wei Huang4, Xian-Dong Zhu1, Fu-Biao Ni1, Guo-Di Wu5, Zi-Qiang Xu6, Zhou-Qing Huang2, Bi-Cheng Chen1, Fang-Yi Xiao2.
Abstract
Although islet transplantation has been identified as a promising endocrine replacement treatment for patient with diabetes mellitus (DM), it still remains unclear whether islet transplantation can inhibit the diabetic-induced myocardial injury and subsequent adverse ventricular remodeling. Here, we sought to explore the molecular mechanism underlying the cardioprotective effect of islet transplantation. We established the diabetic rat model by intraperitoneal injection of STZ, which was followed by either islet transplantation or conventional insulin treatment. Compared with insulin treatment, islet transplantation further reduced the elevated blood glucose which was nearly restored to normoglycaemia. In addition, islet transplantation attenuated the increased levels of cTn-I and CK-MB, cleaved-caspase-3 in response to DM, and ameliorated diabetic-induced cardiac hypertrophy and interstitial fibrosis, along with improved extracellular matrix (ECM) deposition. Moreover, diabetic rats that underwent islet transplantation had lower expression of TGF-β1 and lower phosphorylation levels of Smad3. Therefore, islet transplantation exerted protective effect against diabetic-induced myocardial injury and fibrotic remodeling through deactivation of TGF-β1/Smad3 signaling pathway.Entities:
Keywords: Diabetes mellitus; TGF-β1/Smad3 signaling; cardiac fibrosis; islet transplantation
Year: 2018 PMID: 30210683 PMCID: PMC6129535
Source DB: PubMed Journal: Am J Transl Res Impact factor: 4.060